Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 25, 2018 07:00 ET | Source: Summit Therapeutics plc

Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial

Increase in Utrophin Protein Expression ObservedSummit Accelerating Preparations for Pivotal Clinical TrialEzutromid is a Potential Disease-Modifying Treatment for the Entire DMD Patient...
November 09, 2017 07:00 ET | Source: Summit Therapeutics plc

Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at 15th Action Duchenne International Conference

New Preclinical Data Show Utrophin’s Positive Effect on Mitochondria Improving Muscle Health in DMD Model OXFORD, United Kingdom, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc...
September 25, 2017 07:00 ET | Source: Summit Therapeutics PLC

Summit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne Muscular Dystrophy

OXFORD, United Kingdom, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT)(AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
June 22, 2017 07:00 ET | Source: Summit Therapeutics PLC

Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress

OXFORD, United Kingdom, June 22, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
December 15, 2016 07:00 ET | Source: Summit Therapeutics PLC

Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational Progress

OXFORD, United Kingdom, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
November 16, 2016 07:00 ET | Source: Summit Therapeutics PLC

Summit Enrols Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMD

OXFORD, United Kingdom, Nov. 16, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
October 04, 2016 07:01 ET | Source: Summit Therapeutics PLC

Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

OXFORD, United Kingdom, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
October 04, 2016 07:00 ET | Source: Summit Therapeutics PLC; Sarepta Therapeutics

Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

Sarepta and Summit collaborate to advance the development of novel therapies for patients with Duchenne muscular dystrophySummit receives $40 million upfront, with potential future ezutromid-related...
September 27, 2016 07:00 ET | Source: Summit Therapeutics PLC

Summit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular Dystrophy

OXFORD, United Kingdom, Sept. 27, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
September 26, 2016 07:00 ET | Source: Summit Therapeutics PLC

Summit Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular Dystrophy

OXFORD, United Kingdom, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...

Next Page keyboard_arrow_right